pharmaphorum

JULY 15, 2022

SAE Media Group’s 5th Annual Ophthalmic Drugs Conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing good clinical trial data. Drug delivery will also be an important aspect of the agenda, with advancements in novel technologies. And many more!

Gene Therapy 52

Gene Therapy Drugs Drug Delivery Clinical Trials 52

pharmaphorum

APRIL 29, 2021

Uncover advances in CNS gene therapy , new generation vectors for intravenous delivery, and the challenges of scaling up for CNS delivery beyond highly specialized centers. The high concentration of scientists who face similar challenges makes this Summit so essential to the development of the field.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

pharmaphorum

NOVEMBER 7, 2022

The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies. The conference is co-chaired by Mitchell A.

Drugs 52

Drugs Gene Therapy Clinical Trials Clinical Trials 52

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA drugs are considered to offer an effective alternative to gene therapies, specifically for protein replacement, as they avoid the risk of genome integration and offer strong transient expression.

Vaccine 52

Vaccine Vaccination DNA Protein 52

The Pharma Data

JUNE 26, 2021

About Roche in Ophthalmology Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Our early stage pipeline includes gene therapies and treatments for geographic atrophy and other vision-threatening diseases, including rare and inherited conditions.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

Delveinsight

FEBRUARY 14, 2021

The health regulatory agencies all over have issued several guidelines, released strategies, and amended regulations to expedite the drug delivery process in the rare disease market landscape.

Marketing 52

Marketing Clinical Trials Clinical Trials Trials 52

The Pharma Data

MAY 15, 2023

Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. Another key focus area will be the creation of a framework to develop advanced nano-delivery systems.

Drug Delivery 242

Drug Delivery RNA Development Drugs 242

The Pharma Data

APRIL 12, 2023

Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

Antibody 40

Antibody In-Vitro Development Trials 40

Roots Analysis

SEPTEMBER 22, 2023

These innovative instruments combine precision, convenience, and patient-centered design to revolutionize drug delivery. These devices are equipped with advanced features like programmable dosing, connectivity to mobile apps, and safety mechanisms to ensure accurate and controlled drug delivery.

Drug Delivery 40

Drug Delivery Marketing Insulin Drugs 40

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.

RNA 52

RNA Drug Delivery Engineer Gene Therapy 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

pharmaphorum

JUNE 29, 2022

Among launches resilient for these reasons were Tepezza, an orphan thyroid eye disease medication in the US, Zolgensma, a gene therapy for Spinal Muscular atrophy in Germany, and more recently Evrysdi, an oral agent for the same condition. Orphan drugs launch challenges.

Doctors 59

Doctors Doctor Medicine Sales 59

Pharmaceutical Technology

NOVEMBER 21, 2022

Additionally, the wide-ranging expertise of RVAC in mRNA, vaccine and drug delivery technologies, and its capabilities in research and development (R&D), biopharmaceutical manufacturing, clinical development and marketing is leveraged under the partnership. “We

Manufacturing 130

Manufacturing Medicine Vaccine Vaccination 130

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

Roots Analysis

MAY 21, 2024

In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drug delivery due to the various advantages offered by them.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

The Pharma Data

MAY 5, 2021

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). Affinia Therapeutics raises $110 million for gene therapy treatments ( STAT ). Startup sets out to tackle the gene therapy manufacturing crisis ( Endpoints ). Medtech. Medtech.

Vaccine 52

Vaccine Vaccination Gene Therapy Contract Packaging 52